Co-expression of TNF receptors 1 and 2 on melanomas facilitates soluble TNF-induced resistance to MAPK pathway inhibitors.
Cindy A SanderElizabeth A RushJian ShiLidia M R B ArantesRaymond J TesiMark A RossMichael J CalderonSimon C WatkinsJohn M KirkwoodRobert L FerrisLisa H ButterfieldLazar VujanovicPublished in: Journal of translational medicine (2022)
Our data suggest that TNFR2 is essential to solTNF-induced MAPKi resistance and a possible biomarker to identify melanoma patients that can benefit from solTNF-targeting therapies.
Keyphrases
- end stage renal disease
- high glucose
- rheumatoid arthritis
- diabetic rats
- chronic kidney disease
- ejection fraction
- poor prognosis
- newly diagnosed
- oxidative stress
- signaling pathway
- prognostic factors
- peritoneal dialysis
- electronic health record
- patient reported outcomes
- machine learning
- big data
- cancer therapy
- cell proliferation
- data analysis